Investigational drug · Phase 3
Active Comparator vaccine
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Epidemic Meningitis, Meningococcal Vaccines, Herpes Zoster.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
151
Any phase or sponsor naming "Active Comparator vaccine"
First trial start
2026
Jan 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Active Comparator vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epidemic Meningitis
- Meningococcal Vaccines
- Herpes Zoster
Approved drugs for the same conditions: Herpes and shingles · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Active Comparator vaccine" as an intervention, largest first.
AstraZenecaAstraZeneca (AZN)
NCT05126992 · 5,321,930 participants · Start Feb 18, 2022 · Primary completion Jan 24, 2024
Drug: AZD1222 · For: COVID-19, Vaccine Adverse Events of Special Interest
Sites: Utrecht, Netherlands; Barcelona, Spain; Valencia, Spain · 4 sites in all
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgePivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT06602024 · 40,805 participants · Start Sep 16, 2024 · Primary completion Aug 21, 2025
Drug: mRNA-1010; Fluarix® and 3 more · For: Seasonal Influenza
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 301 sites in all
- Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the ElderlyPivotal-lookingCompleted
MedicagoIndustry
NCT03739112 · 12,794 participants · Start Sep 18, 2018 · Primary completion May 17, 2019
Drug: Quadrivalent VLP Vaccine; Fluarix Quadrivalent® Comparator Vaccine · For: Virus Diseases; RNA Virus Infections; Respiratory Tract Diseases and 1 more
Sites: Mobile, Alabama; Tempe, Arizona; Banning, California · 104 sites in all
- A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and IndiaPivotal-lookingStatus unknown
PATHAcademic, hospital or other
NCT04010448 · 8,200 participants (planned) · Start Oct 10, 2019 · Primary completion Dec 15, 2025
Drug: TV P2-VP8; Rotarix · For: Rotavirus Infection of Children
Sites: Lusaka, Zambia
- A Study to Evaluate a PIKA Rabies Vaccine(Vero Cell)for Human Use,Freeze-driedPivotal-lookingStatus unknown
Yisheng Biopharma (Singapore) Pte. Ltd.Industry
NCT05667974 · 4,500 participants · Start Sep 22, 2023 · Primary completion Mar 22, 2024
Drug: PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried; Chirorab · For: Rabies; Prevention
Sites: Islamabad, Pakistan; Karachi, Pakistan; Lahore, Pakistan · 7 sites in all
- Immuno-bridging Study of COVID-19 Protein Subunit Recombinant VaccinePivotal-lookingCompleted
PT Bio FarmaIndustry
NCT05433285 · 4,050 participants · Start Jun 7, 2022 · Primary completion Aug 5, 2022
Drug: COVID-19 Protein Subunit Recombinant Vaccine; Active Comparator · For: COVID-19
Sites: Semarang, Indonesia; Jakarta, Indonesia; Makassar, Indonesia · 4 sites in all
- A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and OlderPivotal-lookingCompleted
Jiangsu Province Centers for Disease Control and PreventionResearch network
NCT02710409 · 3,664 participants · Start Jan 2016 · Primary completion Jun 2016
Drug: Quadrivalent influenza vaccine; Trivalent influenza vaccine A and 1 more · For: Influenza
Sites: Lianyungang, China
- Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the CongoPivotal-lookingNot yet recruiting
Jean-Pierre Van geertruydenAcademic, hospital or other
NCT07842107 · 3,620 participants (planned) · Start Oct 20, 2026 · Primary completion Apr 2027
Drug: Candidate BDBV vaccine; Active comparator · For: Ebola Hemorrhagic Fever; Bundibugyo Virus Disease
Sites: Bunia, Democratic Republic of the Congo
- Clinical Trial of 13-Valent Pneumococcal Conjugate VaccinePivotal-lookingRecruiting
Sinovac Life Sciences Co., Ltd.Industry
NCT06617715 · 3,080 participants (planned) · Start Oct 23, 2024 · Primary completion May 12, 2026
Drug: Sinovac PCV13; Prevnar® · For: Pneumococcal Infectious Disease
Sites: Zhengzhou, China
- Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)Pivotal-lookingCompleted
PT Bio FarmaIndustry
NCT04051268 · 3,071 participants · Start Mar 2, 2020 · Primary completion Nov 24, 2021
Drug: Vi-DT Typhoid Conjugate Vaccine; PQed Typhoid Conjugate Vaccine and 1 more · For: Safety Issues; Immunogenicity
Sites: Jakarta, Indonesia
Newest research
PubMed records naming it or its code names, newest first.
- Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Chinese Children, Adults and the Elderly: A Phase 4, Randomized, Double-Blind, Active-Controlled Clinical Trial.
Liu X, Shi G, Dong Y, et al. · Vaccines (Basel) 2025
- COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
Fleming TR, Krause PR, Nason M, et al. · Clin Trials 2021
- Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].
Duggan ST, Plosker GL · Drugs 2009
Also in development for Epidemic Meningitis
- experimental vaccinePhase 34 trials
Sinovac Biotech Co., Ltd · Epidemic Meningitis, Meningococcal Vaccines
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.